Clinical trials · New York
Malignant Neoplasm clinical trials in New York
We’re tracking 72 recruiting malignant neoplasm studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
Brooklyn, New YorkAges 18 years+ - NCT07042581RecruitingPhase 4
Revaree Plus for vaginal dryness in breast cancer survivors
This trial tests a vaginal insert called Revaree Plus to see if it helps breast cancer survivors who have vaginal dryness or pain from hormone therapy. It may be a good option if you are on an aromatase inhibitor or tamoxifen and have discomfort.
Commack, New YorkAges 18 years+ - NCT04804644RecruitingPhase 3
Memory-sparing radiation for brain metastases in small cell lung cancer
This study tests whether focusing high-dose radiation only on brain tumor spots, while avoiding the hippocampus (a brain area important for memory), helps protect memory and thinking compared with standard whole-brain radiation. It’s for people with small cell lung cancer that has spread to the brain.
Canandaigua, New YorkAges 18 years+ - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Stony Brook, New YorkAges Any age - NCT06422455Recruiting
Genetic testing for underserved cancer patients
This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.
Rochester, New YorkAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Buffalo, New YorkAges 18 years+ - NCT06295367Recruiting
Cost Communication and Financial Help for Newly Diagnosed Cancer Patients
This study looks at whether talking openly about treatment costs and providing guidance to find financial help can make a difference for people with newly diagnosed solid tumors. If you join, you will be asked to fill out surveys about your experience.
The Bronx, New YorkAges Any age - NCT05642611RecruitingPhase 3
Cooling and compression for nerve protection during chemotherapy
This study tests whether using cooling and/or compression on the arms or legs can prevent nerve damage that can happen from certain chemotherapy drugs. If you get eligible chemo soon, this may help lower the chance of painful numbness or tingling during treatment.
Syracuse, New YorkAges 18 years+ - NCT04871542Recruiting
Predicting risk of immune therapy side effects
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Cortlandt Manor, New YorkAges 18 years+ - NCT07572006RecruitingPhase 1
Study of JNJ-95804306 for blood cancers that returned or didn't respond
This trial tests a new drug called JNJ-95804306 for people with certain blood cancers (like acute myeloid leukemia, myelodysplastic syndromes, or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The goal is to see if the drug is safe and if it can help.
New York, New YorkAges 18 years+ - NCT04511039RecruitingPhase 1
New targeted pill combo for advanced colon or stomach cancers
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
Buffalo, New YorkAges 18 years+ - NCT05006482RecruitingPhase 3
Geriatric education and care support for older cancer survivors
This study tests whether a structured health education and “older adult care” approach—done with your oncology team—can improve support for people after cancer. It includes older cancer survivors and a chosen caregiver, using in-person or video visits for follow-up.
Rochester, New YorkAges 18 years+ - NCT02285582Recruiting
Rare blood disorder registry for histiocytic conditions
This study is a registry that collects information about people diagnosed with rare histiocytic disorders. It helps doctors better understand these conditions over time and may improve future care.
New York, New YorkAges Any age - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
New York, New YorkAges 18 years+ - NCT07283939Recruiting
Testing a tool to adjust chemo doses and reduce treatment delays
This trial tests a computer algorithm called PAGODA that helps doctors adjust chemotherapy doses for people with gastrointestinal cancers. The goal is to prevent unplanned treatment delays while keeping the treatment effective.
The Bronx, New YorkAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Brooklyn, New YorkAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
New York, New YorkAges 18 years+ - NCT06655246RecruitingPhase 1
Ziftomenib and imatinib for advanced GIST
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
New York, New YorkAges 18 years+ - NCT05893940Recruiting
Gentle physical stimulation during blood cancer transplant
This trial tests whether a low-intensity mechanical (physical) stimulation is safe and helpful for people with certain blood cancers who are about to have a transplant. It may affect how you do during or after treatment, and participation is voluntary with informed consent.
Buffalo, New YorkAges 18 years+ - NCT05875805Recruiting
Telehealth planning for future care decisions
This trial tests a telehealth (video or phone) program that helps people with certain blood cancers plan their future care preferences. It may help you and your chosen support person communicate your wishes clearly, especially if you become too sick to speak for yourself.
Rochester, New YorkAges 60 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
New York, New YorkAges 18 years+ - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Buffalo, New YorkAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
New York, New YorkAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
New York, New YorkAges 18–66
Malignant Neoplasm trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting malignant neoplasm studies listed above.
- Memorial Sloan Kettering Cancer Center · 9 studies
- NYU Langone Health · 7 studies
- University of Rochester · 6 studies
- Roswell Park Cancer Institute · 5 studies
- Columbia University Irving Medical Center · 4 studies
- Montefiore Medical Center · 4 studies
- State University of New York Upstate Medical University · 4 studies
- Memorial Sloan Kettering Commack · 3 studies
What taking part in a malignant neoplasm study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Malignant Neoplasm trials in other states
Common questions
- Are there malignant neoplasm clinical trials in New York?
- Yes. We're currently tracking 72 recruiting malignant neoplasm studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a malignant neoplasm study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a malignant neoplasm trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New malignant neoplasm studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.